High-density lipoprotein inhibits serum amyloid A–mediated reactive oxygen species generation and NLRP3 inflammasome activation

ABSTRACT
Serum amyloid A (SAA) is a high-density apolipoprotein whose plasma levels can increase more than 1000-fold during a severe acute-phase inflammatory response and are more modestly elevated in chronic inflammation. SAA is thought to play important roles in innate immunity, but its biological activities have not been completely delineated. We previously reported that SAA deficiency protects mice from developing abdominal aortic aneurysms (AAAs) induced by chronic angiotensin II (AngII) infusion. Here, we report that SAA is required for AngII-induced increases in interleukin-1 beta (IL-1β), a potent proinflammatory cytokine that is tightly controlled by the Nod-like receptor protein 3 (NLRP3) inflammasome and caspase-1 and has been implicated in both human and mouse AAAs. We determined that purified SAA stimulates IL-1β secretion in murine J774 and bone marrow–derived macrophages through a mechanism that depends on NLRP3 expression and caspase-1 activity, but is independent of P2X7 nucleotide receptor (P2X7R) activation. Inhibiting reactive oxygen species (ROS) by N-acetyl-L- cysteine or mito-TEMPO and inhibiting activation of cathepsin B by CA-074 blocked SAA-mediated inflammasome activation and IL-1β secretion. Moreover, inhibiting cellular potassium efflux with glyburide or increasing extracellular potassium also significantly reduced SAA-mediated IL-1β secretion. Of note, incorporating SAA into high-density lipid (HDL) prior to its use in cell treatments completely abolished its ability to stimulate ROS generation and inflammasome activation. These results provide detailed insights into SAA-mediated IL-1β production and highlight HDL’s role in regulating SAA’s proinflammatory effects.

Interleukin-1β (IL-1β) is a key proinflammatory mediator in acute and chronic inflammation and a powerful inducer of the innate immune response (1). A growing body of evidence currently points to IL-1β as a major player in a wide variety of chronic diseases (2). Consistent with this concept, randomized clinical trials have shown that blocking IL-1β signaling leads to a sustained reduction in systemic inflammation and improvement in type2 diabetes patients (3). More recently, the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS), significantly lowers the rate of cancer mortality and recurrent cardiovascular events compared to placebo, independent of lipid-lowering (4). However, there was also a significant increase in deaths from infection in patients who received canakinumab, leading to an overall neutral effect on mortality in the CANTOS trial. Thus, understanding the endogenous mechanisms leading to elevated IL-1β production in chronic inflammatory diseases are needed in order to develop effective strategies for anti-IL-1β therapy that avoid an overall suppression of immune responses.The production of bioactive IL-1β is tightly controlled by the inflammasome, a multi- protein intracellular complex that serves as a platform for the proteolytic maturation of IL-1β. The well-studied of these complexes is the NLRP3 inflammasome, which is comprised of a scaffold protein, NLRP3; an adaptor protein, ASC; and the cysteine protease, pro-caspase1. Two signals are required for NLRP3 inflammasome activation. The first signal requires a stimulus that induces the transcription of key components of the inflammasome including IL-1β and NLRP3. This “priming” signal typically involves nuclear factor (NF)-kB activation induced by signaling through a toll- like receptor or other pattern recognition receptors (5).

Pathogen-associated or host- derived factors may prime the inflammasome innon-sterile and sterile inflammatory diseases, respectively (6). The second signal promotes the functional activity of the NLRP3 inflammasome. A variety of structurally diverse molecules, including bacterial toxins, ATP, uric acid crystals, silica, asbestos, alum, cholesterol crystals and amyloid-β are known to activate the NLRP3 inflammasome (5). Interestingly, minimally modified LDL has been suggested to provide both signal 1 and signal 2 in macrophage foam cells, the latter most likely through the intracellular accumulation of cholesterol crystals (7).Another danger-associated molecule capable of both priming and activating the NLRP3 inflammasome is serum amyloid A (SAA). SAA stimulates secretion of IL-1β in human and mouse macrophages, dendritic cells and neutrophils (8-10). SAA represents a family of proteins with 103-104 amino acids that share high sequence homology that presumably arose from gene duplication. In humans, three SAA isoforms are expressed, SAA1, SAA2, and SAA4, which correspond to the highly homologous mouse SAA1.1, SAA2.1, and SAA4. Mice express a fourth SAA, SAA3, which is a pseudogene in humans due to a premature stop codon in the coding sequence (11). Whereas SAA4 is a constitutively expressed isoform that is present in plasma at relatively low concentrations (12), the other SAAs are acute-phase proteins that are highly induced during an acute inflammatory response (13). During severe inflammation such as sepsis, SAA can account for as much as 2.5% of hepatic protein production, with serum SAA levels increasing >1000-fold(13), suggesting an important role for SAA in the immediate response to tissue injury and infection. On the other hand, chronically elevated SAA is associated with a wide variety of chronic pathological conditions (14,15).

Although circulating SAA is thought to be primarily produced by hepatocytes, extra-hepatic synthesisof SAA has been reported in inflamed tissues (16,17). Virtually all of circulating SAA is bound to the surface of high-density lipoprotein (HDL) (18). SAA binds a wide range of molecules including heparan sulfate proteoglycans (19), extracellular matrix proteins(20) and pattern recognition receptors such as formyl peptide receptor-like 1 (FPRL-1) (21), FPRL-2 (22), TLR2 (23), TLR4 (24), SR-B1(25) and CD36 (26). Despite accumulating evidence that SAA is a key mediator in innate immunity and is associated with numerous chronic inflammatory conditions, SAA’s functions in immune responses and inflammatory diseases have not been clearly established.In a previous publication, we reported that SAA deficiency attenuates abdominal aortic aneurysm (AAA) formation in the mouse angiotension II (AngII) infusion model (15). In the current study, we determined that reduced AngII-induced AAA in SAA-deficient mice is accompanied by significant reductions in IL-1β, suggesting that inflammasome activation in AngII-infused mice is dependent on SAA. This finding is notable given extensive evidence that IL-1β and NLRP3- mediated inflammasome activation promote experimental aortic aneurysms in mice (27-32) and the observation that circulating levels of IL-1β is elevated in patients with AAA (33). We also report that SAA activates the NLRP3 inflammasome through the generation of reactive oxygen species, cathepsin B activation, and potassium efflux. Notably, HDL blocks the ability of SAA to mediate NLRP3 activation. These data further our understanding of an endogenous factor that may mediate pathophysiological effects in the setting of chronic inflammation.

Results
We previously reported that lack of endogenous acute-phase SAA1.1 and SAA2.1 protects apoE-/- mice from angiotensin II (AngII)-induced AAA formation (15). In a recent study, Usui et al. determined that deficiency in either NLRP3 or caspase-1prevents AngII-induced AAA in apoE-/- mice, establishing that activation of the NLRP3 inflammasome is a necessary event for AAA development in this animal model (29). Therefore, it was of interest to investigate whether SAA mediates inflammasome activation in AngII-infused apoE-/- mice. Accordingly, we assessed plasma IL-1β levels after 28-day AngII infusion in apoE-/- mice and apoE-/- mice lacking SAA1.1 and SAA2.1 (apoE-/- x SAA1.1/2.1-DKO mice). IL-1β was not detected in the plasma of either strain of mice prior to AngII infusion. Notably, the increase in plasma IL-1β levels observed in AngII-infused apoE-/- mice was significantly blunted in apoE-/- x SAA1.1/2.1-DKO mice (Fig. 1A). As a gain- of-function approach, we overexpressed SAA1.1 in apoE-/- x SAA1.1/2.1-DKO mice using adeno- associated virus (AAV)-mediated gene transfer. Fourteen days after AAV injections, the mice were infused with AngII for 28 days. Interestingly, there was a significant increase in plasma IL-1β in mice injected with AAV- SAA1.1 compared to mice injected with control AAV-null following AngII infusion (Fig. 1B). These results indicate that SAA plays a central role in AngII-induced IL-1β production, a key event in AngII-induced AAA.The observation that SAA is required for increased plasma IL-1β in mice infused with AngII prompted us to investigate whether SAA regulates IL-1β production in macrophages. J774 cells incubated with 50 µg/ml purified mouse SAA (a mixture of SAA1.1 and SAA2.1, as well as small amounts of SAA3 (34) that has undetectable levels of endotoxin) for 8 h showed a significant 16-fold increase in pro-IL-1β mRNA (Fig. 2A). SAA also evoked a dose- and time-dependent increase in IL-1β secretion (Fig. 2B and C). Human (hSAA) isolated from the HDL fraction of cardiac surgery patients was also effective in inducing IL-1β mRNA expression (Fig. 2D) and IL-1β release (Fig. 2E) in J774 cells.We next investigated the role of the NLRP3 inflammasome in SAA-mediated IL-1β release. Our results indicate SAA upregulates NLRP3 mRNA expression ~3-fold in J774 cells (Fig. 3A), consistent with inflammasome “priming”. The second “activation” step involves the intracellular assembly of the inflammasome complex, which in turn leads to the proteolytic activation of caspase-1. Immunoblot analysis showed increased cleavage of caspase-1 to its active p20 subunit in J774 cells incubated for 24 h with 50 µg/ml mouse SAA compared to untreated control cells (Fig. 3B).

SAA-induced IL-1β secretion was blocked when cells were treated with YVAD, a specific caspase-1 inhibitor (35) (Fig. 3C). To determine whether SAA-induced IL-1β secretion is dependent on NLRP3, bone-marrow-derived macrophages (BMDMs) isolated from C57BL/6 (WT) and NLRP3-/- mice were treated with 5 µg/ml mouse SAA for 24 h. As shown in Fig. 3D, IL-1β secretion induced by SAA was significantly lower (more than 10-fold) in BMDMs from NLRP3-/- mice compared to cells from WT mice. These results indicate that SAA stimulates IL-1β secretion in macrophages mainly through NLRP3 inflammasome-mediated caspase-1 activation.SAA-mediated inflammasome activation involves alterations in cellular K+ flux that are independent of the P2X7 receptor.Potassium efflux and reduced intracellular K+ have been linked to NLRP3 inflammasome activation in monocyte/macrophages triggered by numerous known NLRP3 activators, such as ATP, nigiricin, alum, and silica (5). Hence, we investigated whether an alteration in cellular K+ efflux was involved in SAA-mediated IL-1β release in J774 cells. Incubation of J774 cells with mouse SAA (5µg/ml) along with a K+ channel blocker, glyburide (200 µM), or increased extracellular K+ concentration (20 mM), completely abolished SAA-mediated IL- 1β release (Fig. 4A), demonstrating that SAA- mediated NLRP3 activation requires alterations in cellular K+ flux. One well-established pathway for activating NLRP3 through increased K+ efflux is by means of the trimeric ATP-gated cation channel, P2X7. The P2X7receptor expressed by macrophages is activated by extracellular ATP to induce NLRP3 inflammasome assembly and release of IL-1β (36). To investigate whether the P2X7 receptor is required for the SAA-induced release of IL- 1β, J774 cells were treated with purified SAA in the presence or absence of specific P2X7 receptor antagonists, AZ10606120 and A438079. The effectiveness of AZ10606120 to block NLRP3 inflammasome-mediated IL-1β release was confirmed in control experiments whereby J774 cells were primed with LPS and then stimulated with ATP (Fig. 4B). In contrast, both AZ10606120 and A438079 were completely ineffective in blocking the robust release of IL-1β produced in J774 cells after 24 h incubations with purified mouse SAA (5 µg/ml; Fig. 4C).

Inhibition of P2X7 receptor signaling also failed to reduce SAA-induced conversion of pro-caspase-1 to the active form (Fig. S1). Taken together, our data indicate that SAA-mediated inflammasome activation is dependent on changes in intracellular K+ through a mechanism that is independent of the P2X7 receptor. Reactive oxygen species (ROS) have been shown to be essential for NLRP3 inflammasome activation (5). ROS generation is frequently accompanied by K+ efflux, although the interplay between these pathways is currently not clear, with low intracellular K+ concentration stimulating ROS production and vice versa (37). To investigate the possibility that SAA mediates activation of NLRP3 inflammasomes through ROS generation, J774 cells were treated with or without 5 µg/ml mouse SAA for 24 h, and cellular ROS levels were quantified using a cell permeant fluorescent reagent, 2’,7’–dichlorofluorescin diacetate (DCFDA). ROS levels were significantly higher (2.2-fold) in J774 cells treated with SAA compared to untreated cells. Co-incubation with a free-radical scavenger, N- acetyl-cysteine (NAC) significantly reduced SAA-dependent ROS generation by 58% (Fig. 5A). This decrease in SAA-dependent ROS generation was accompanied by a 78% decreasein the amount of IL-1β released in SAA- stimulated cells (Fig. 5B). SAA-mediated priming, as evidenced by IL-1β mRNA levels in SAA-treated cells, was not significantly affected by NAC treatment (Fig. 5C). These results indicate that ROS generation is a prerequisite for SAA-mediated inflammasome activation. We next assessed SAA-mediated IL-1β release in the presence of mito-TEMPO, a scavenger specific for mitochondrial ROS. Interestingly, mito-TEMPO caused a significant inhibition of SAA-mediated IL-1β release (Fig. 5D). Similar to J774 cells, treatments with NAC or mito- TEMPO significantly suppressed SAA-mediated IL-1β release from C57BL/6 BMDMs (Fig. 5E and F).

These results indicate that SAA- mediated inflammasome activation is dependent on mitochondrial ROS generation.Disruption of lysosomal membranes caused by phagocytosis of particulate matter, live pathogens or sterile lysosomal damage results in NLRP3 activation (5). The ensuing release of the lysosomal aspartyl protease cathepsin B into the cytoplasm triggers inflammasome activation either directly or indirectly through a poorly understood mechanism. Interestingly, we determined that incubations with CA-074-Me, a specific inhibitor of cathepsin B, resulted in a significant 46% decrease in IL-1β release induced by SAA (Fig. 6A). Inhibition of cathepsin L had no effect on SAA-induced IL-1β release. One mechanism for inducing lysosomal damage and subsequent cathepsin B release is through the phagocytosis of extracellular fibrils and crystals, such as amyloid-beta and cholesterol crystals (38,39). Since SAA is known to be capable of forming extracellular fibrils in AA amyloidosis (40), we considered the possibility that phagocytosis of SAA in the form of extracellular fibrils results in lysosomal damage and subsequent NLRP3 inflammasome activation. However, treatment with 3 µM cytochalasin D to block phagocytosis did not alter IL-1β release stimulated by SAA (Fig. 6B), while it effectively blocked alum- mediated IL-1β secretion in these cells (Fig. 6C).The vast majority of SAA secreted by the liver during an inflammatory response is associated with HDL in plasma (18). Our group previously reported that lipid-poor SAA, but not HDL-associated SAA, stimulates granulocyte colony stimulating factor and TNFα production in macrophage cells (41). HDL suppresses inflammasome activation triggered by cholesterol crystals (42). It was therefore of interest to investigate whether HDL-associated SAA induces IL-1β secretion in J774 cells similarly to purified, lipid-poor SAA. Accordingly, J774 cells were incubated with 5g/ml purified mouse SAA or 5 g/ml SAA associated with HDL (1:2.8 ratio of SAA protein to HDL protein). HDL-associated SAA was significantly reduced in its ability to induce IL- 1β and NLRP3 mRNA expression in J774 cells (Fig. 7A and B) and BMDMs (Fig. 7C), indicating that HDL does indeed block SAA- mediated inflammasome priming.

IL-1β protein release by both J774 cells (Fig. 7D) and BMDMs (Fig. 7E) was also abrogated when SAA was bound to HDL. The two major apolipoproteins of HDL, apo-AI and apo-AII, were ineffective in blocking SAA- stimulated IL-1β secretion; indeed, IL-1β secretion by cells incubated with lipid-free SAA was modestly enhanced by the addition of apoA- I or apoA-II while apoA-I and apoA-II alone were ineffective in inducing IL-1β secretion (Fig. 7F).We investigated the possibility that HDL blocks SAA’s activity by altering the cellular uptake of SAA. J774 cells were treated with 0.5 µg/ml FITC-labeled SAA (green fluorescence) with or without HDL (1.4 µg/ml protein) for 4 h, followed by immunocytochemical staining to visualize lysosomes with fluorescently-labeled anti- LAMP1 antibody (red fluorescence) and nuclei with DAPI (blue fluorescence). Imaging by confocal microscopy indicated that both lipid- free (Fig. 7G) and HDL-bound (Fig. 7H) SAA were readily taken up by J774 cells. Notably, there was no evidence of SAA co-localization with the lysosomal marker LAMP-1 for either experimental condition. These data suggest that the mechanism by which HDL suppresses SAA-mediated inflammasome activation does not involve alterations in cellular uptake or lysosomal accumulation of SAA.Several studies have established that HDL suppresses SAA signaling through TLR4 (41,43,44), suggesting that the lack of induction of IL-1β secretion by cells treated with HDL- associated SAA may merely reflect the absence of SAA-induced IL-1β mRNA expression (i.e., inflammasome priming).

Thus, it was of interest to determine whether HDL prevents SAA- mediated inflammasome priming, or both priming and activation. To specifically address this question, J774 cells were pre-treated with0.5 µg/ml LPS to induce IL-1β and NLRP3 expression, and then washed to remove the LPS. The primed cells were then treated with 5 µg/ml lipid-free mouse SAA or SAA associated with HDL. In contrast to lipid-free SAA, HDL- associated SAA was ineffective in inducing IL- 1β release even after priming the cells with LPS (Fig. 8A), indicating that HDL masks not only SAA-mediated priming, but also SAA-mediated inflammasome activation.We considered the possibility that the ability of HDL to interfere with SAA’s effects may be due to a general effect of HDL to impede inflammatory responses in cells. J774 cells were sequentially incubated with LPS (0.5 µg/ml) for 3 h followed by 3 mM ATP for 45 min in the absence and presence of 70 µg/ml HDL. Interestingly, HDL did not significantly impede LPS-mediated priming or ATP-mediated activation of inflammasomes, as assessed by the induction of IL-1β mRNA expression (Fig. 8B) and protein secretion (Fig. 8C), respectively.As an alternate analysis of inflammasome activation, J774 cells were treated with or without 5 µg/ml lipid-free or HDL-associated mouse SAA for 24 h and then labeled with FAM-YVAD-FMK (FLICA), a fluorescent caspase-1 inhibitor that binds activated caspase-1 but not pro-caspase-1 (45). Fluorescence microscopy showed increased FLICA staining for cells treated with lipid-free SAA, but not SAA bound to HDL, compared to control untreated cells (Fig. 8D).Notably, the ability of HDL to interfere with SAA-induced caspase-1 activation and IL- 1β secretion was associated with a significant effect on SAA-mediated ROS generation in J774 cells (Fig. 8E).

Discussion
In this study, we determined that SAA is required for the increased IL-1β production that occurs in mice chronically infused with AngII. This finding has potential clinical implications, given the accumulating evidence that IL-1β and NLRP3 inflammasome activation play a critical role in the development of human and mouse AAA (27-32) and our previous report that SAA mediates AngII-induced AAA in mice (15). Circulating SAA is elevated in a number of chronic inflammatory diseases including obesity, type 2 diabetes, rheumatic diseases, cancer, and cardiovascular diseases where IL-1β is thought to play a pathological role. Thus, understanding the pathways by which SAA stimulates IL-1β production may provide novel insights into chronic disease mechanisms and hence was the focus of our current studies.Other groups have reported that SAA stimulates dendritic cells, macrophages, and neutrophils to secrete IL-1β by activating the NLRP3 inflammasome (8-10). However, these studies utilized a recombinant SAA protein that has 2 amino acid substitutions (at positions 61 and 72) when compared to native SAA1, and recent evidence suggests that this recombinant form of SAA may exert activities not shared by mouse or human SAA (46,47). In our studies investigating SAA-mediated IL-β expression and secretion we utilized SAA isolated from acute phase mouse or human plasma to facilitate interpretation of results. The purified SAA preparations contained a mixture of the acute phase SAA isoforms, namely SAA1 and SAA2 in humans, and SAA1.1, SAA2.1, and to a lesser extent, SAA3 in mice. While mouse SAA1.1 and SAA2.1 are highly homologous (91% amino acid conservation) and are coordinately regulated, functional differences have been identified. Most notably, SAA1.1, and not SAA2.1, has a propensity to be deposited extracellularly as insoluble amyloid fibrils (48). Modest differences in the capacity to promote cellular cholesterol efflux and interact withpattern recognition receptors have also been noted for the two isoforms (49,50). Whether individual acute phase SAA isoforms differ in their ability to trigger IL-1β secretion merits future study.

SAA’s ability to activate NF-κB pathways (the “priming” step) by signaling through multiple pattern recognition receptors is widely recognized. Thus, the induction of IL-1β and NLRP3 mRNA expression in J774 macrophage-like cells incubated with SAA was not unexpected. The ability of SAA to both prime and activate the NRLP3 inflammasome to stimulate IL-1β secretion in J774 cells distinguishes it from the myriad of compounds such as ATP, pore-forming toxins (51), amyloid beta (14,38) and cholesterol crystals (7) that are incapable of inducing IL-1β secretion in the absence of a priming stimulus. Thus, SAA seems to constitute an endogenous ‘danger’ signal with the unique ability of stimulating both essential steps of NLRP3 inflammasome- mediated IL-1β secretion.Although the precise mechanism bywhich the NLRP3 inflammasome is activated in cells remains unknown, several stress-related cellular processes, including cytosolic depletion of potassium, lysosome disruption, mitochondrial damage or generation of ROS have been proposed to be involved (5). For example, extracellular ATP released by damaged cells binds the ATP-gated P2X7 receptor and activates the NLRP3 inflammasome through the rapid production of ROS (36). In an earlier report, inhibitors of P2X7 receptor signaling significantly abrogated IL-1β release by human monocyte-derived macrophages treated with recombinant human SAA (9). Based on this finding, the authors proposed that SAA directly interacts with this receptor to stimulate NLRP3 activation (9). However, in the present study with endogenous, purified mouse SAA, we did not observe an inhibition of SAA-mediated IL-1β release with P2X7 receptor antagonists. The discrepancy with the previous report may be due to differences in properties between recombinant and purified native SAA.

SAA is known to mediate ROS generation in neutrophils and Swiss 3T3 fibroblast cells (52,53). A previous study indicated that mitochondrial ROS-dependent and –independent mechanisms play a part in SAA-mediated inflammasome activation (54). In the current study, we demonstrate that SAA enhances ROS generation in J774 cells and that inhibition of ROS by the cytosolic ROS scavenger, NAC and mitochondrial ROS scavenger, mito-TEMPO cause a significant decrease in SAA-mediated IL-1β release (Fig. 5). Inhibiting cathepsin B activity potently abrogated IL-1β release by cells incubated with purified mouse SAA, consistent with previous results with recombinant SAA (9). These data suggest that SAA mediates NLRP3 inflammasome activation through a mechanism involving lysosomal degradation and protease release(5). Interestingly, cathepsin B is known to be involved in the proteolytic processing of SAA resulting in AA amyloid proteins (55). Whether cathepsin B-mediated proteolytic processing of SAA leads to NLRP3 inflammasome activation needs to be investigated.We report a role for K+ efflux in SAA- mediated IL-1β release. Potassium efflux has been shown to be required for NLRP3 activation by various inflammasome stimuli (56,57). Thus, it appears that SAA mediates inflammasome activation through multiple pathways. Whether these processes are interlinked or act independently is currently unclear. Evidence suggests that other NLRP3 activators induce lysosomal disruption, ROS generation, and K+ efflux, which apparently act in concert to ultimately lead to caspase-1 activation and IL-1β maturation (5). For example, in a study of the pathogenesis of osteoarthritis, hydroxyapatite crystal-stimulated IL-1β release was shown to require ROS generation, lysosomal protease release, and K+ efflux (58).The majority of SAA in plasma is associated with HDL, a lipoprotein fraction generally thought to be anti-inflammatory (59,60). During an acute inflammatory response SAA can be the major apolipoprotein on HDL(61). The relationship between the respective functions of SAA and HDL is complex: While HDL enriched in SAA is thought to be impaired in its anti-inflammatory properties (62,63), many of the proinflammatory effects of SAA have been attributed to lipid-free, and not HDL-associated SAA (41).

In our study, we report that HDL completely masks SAA-mediated NLRP3 inflammasome priming and activation. HDL is known to inhibit inflammasome activation by other stimuli including cholesterol crystals, ATP, nigericin, silica and alum (42) in THP-1 cells, a monocytic cell line that requires no priming for inflammasome activation. On the other hand, in our studies, HDL did not alter LPS/ATP- induced IL-1β secretion, even though there was a trend for HDL to decrease LPS-mediated IL- 1β mRNA expression (Fig. 8 B and C). Thus, HDL does not appear to have a global effect on the ability of cells to respond to stimuli that provoke IL-1β release. While the precise mechanism by which HDL protects cells from inflammasome activation has not been clearly delineated, we noted that the effect of HDL to suppress SAA-stimulated IL-1β release was accompanied by a significant reduction in ROS (Fig. 8E). The major apolipoproteins of HDL, apoA-I and apoA-II, were ineffective in blocking SAA’s effects (Fig.7F). Lipid-free apoA-I and apoA-II were also incapable of mimicking SAA’s ability to trigger IL-1β release (Fig.7F).At this time it is unclear how HDL masks SAA’s biological effects. One possibility is there are bioactive motifs on SAA that are masked when SAA is bound to lipoprotein particles. Alternatively, differences in the conformation of SAA in the lipid-free versus HDL-bound form may be critical for its biological activity. Lipid- free SAA possesses a random coil-like conformation at 37oC (64,65), while HDL binding stabilizes SAA into an α-helical conformation (64-66). SAA-induced signaling via the formyl peptide (67), CD36 (26) and toll- like receptors (41) is apparent only with lipid- free SAA, whereas both lipid-free and HDL- bound SAA interact with SR-BI (25). It is possible that once liberated from HDL, SAA undergoes structural changes or becomes susceptible to limited proteolysis and the modified protein triggers inflammasome activation.

Our study, consistent with other reports (68,69) indicates that HDL does not prevent cellular uptake of SAA (Fig.7G and H). According to one report, HDL-SAA is internalized through a clathrin-dependent endocytic pathway and then trafficked tolysosomes where it accumulates as SAA aggregates or amyloid deposits (69). We did not observe localization of SAA in lysosomes in our studies, which involved 4 h treatments (Fig.7G and H). Amyloid fibril formation is believed to occur when the influx of SAA into cells exceeds their proteolytic capacity (69). Amyloid fibrils can cause disruption of lysosomal membranes (69), which may trigger inflammasome activation. However it seems unlikely that SAA fibril formation is responsible for triggering inflammasome activation in our study, as HDL- bound SAA is capable of forming intracellular fibrils (68,69).Under homeostatic conditions, liver- derived SAA is unlikely to trigger inflammasome activation since virtually all of it is bound to HDL. Indeed, transgenic mice with inducible, liver-specific SAA expression do not exhibit increased inflammation despite very high levels of plasma SAA (>1 mg/ml) (70). However, in the right context SAA might be released from HDL in tissues to exert local pro- inflammatory effects. Our finding that AngII- induced increases in IL-1β are significantly blunted in mice lacking acute phase SAAs underscores the fact that SAA has pro- inflammatory effects in pathological settings, such as experimental AAA. SAA concentrations can be dramatically elevated in tissues due to local injury, infection or inflammation (15,71- 74). The relative contribution of locally produced SAA versus HDL-bound SAA that has deposited in tissues at the site of injury or inflammation is not known, and merits further investigation. While inflammasome activation represents a host defense to pathogens and host- derived danger signals, inappropriate or excessive activation results in tissue injury (75). Thus, to protect the host from widespread tissue damage, HDL may serve as a transporter and shield to prevent excessive SAA-mediated systemic inflammasome activation.

Targeted deletion of the saa1.1 and saa2.1 genes in C57BL/6 mice was performed by InGenious Targeting Laboratory, Inc. as described earlier (76). The mice were then crossed with apoE-/- mice to generate apoE-/-mice lacking acute phase SAAs (apoE-/- x SAA1.1/2.1-DKO) (15). For angiotensin II (AngII) infusion studies, animals were housed in microisolator cages and provided normal rodent diet and water ad libitum. AngII (1,000 ng kg-1 min-1; Sigma-Aldrich) or saline was administered via Alzet osmotic minipumps (model 2004; Durect Corporation) to 12-14 week old male mice anesthetized with 50 µl ketamine/xylazine cocktail, 90 and 10 mg/ml, respectively (Ketamine, Butler Schein; Xylazine, Lloyd laboratories) as previously described (77). Plasma was collected 28 days after pump implantation for IL-1β determinations. AAV vectors (serotype were produced by the Viral Vector Core at the University of Pennsylvania. The AAV-SAA1.1 vector contains an insert encoding mouse SAA1.1 (GenBank accession NM_011314). Empty AAV vector (AAV-null) was used as control. For the AAV study, apoE-/- x SAA1.1/2.1 DKO mice were injected i.p with 1 x10e11 particles AAV-SAA1.1 or AAV-null in a total volume of 200 µl sterile saline. Blood samples were collected from the retroorbital sinus at baseline (prior to AAV injections) and 14 days later to confirm that blood SAA levels were elevated in AAV-SAA1.1-treated mice CA-074 Me (typically 300-500 g/ml). AngII pumps were implanted on day 15 as described above. Plasma IL-1β was determined after 28-day AngII infusion. All studies were performed with the approval of the University of Kentucky Institutional Animal Care and Use Committee.